Adherex Technologies (NASDAQ:FENC) Stock Price Crosses Below Fifty Day Moving Average – Here’s What Happened

Shares of Adherex Technologies Inc. (NASDAQ:FENC – Get Free Report) passed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $10.72 and traded as low as $10.27. Adherex Technologies shares last traded at $10.58, with a volume of 228,387 shares.

Wall Street Analyst Weigh In

FENC has been the subject of several research analyst reports. B. Riley Financial reiterated a “buy” rating and set a $18.00 target price (up from $16.00) on shares of Adherex Technologies in a research note on Wednesday, August 12th. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Adherex Technologies in a research report on Wednesday, September 9th. Wedbush boosted their price objective on shares of Adherex Technologies from $13.00 to $16.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adherex Technologies in a report on Thursday, October 15th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Adherex Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $17.00.

View Our Latest Stock Report on Adherex Technologies

Adherex Technologies Stock Performance

The business has a fifty day simple moving average of $10.66 and a two-hundred day simple moving average of $9.34.

Adherex Technologies (NASDAQ:FENC – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.02. Adherex Technologies had a negative return on equity of 5.71% and a negative net margin of 6.09%. The company had revenue of $19.61 million for the quarter, compared to analyst estimates of $18.87 million. Equities research analysts predict that Adherex Technologies Inc. will post 0.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other Adherex Technologies news, insider Pierre Sargis Sayad sold 12,000 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $12.18, for a total transaction of $146,160.00. Following the completion of the transaction, the insider directly owned 9,519 shares in the company, valued at $115,941.42. This represents a 55.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Robert Andrade sold 75,000 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $11.78, for a total value of $883,500.00. Following the transaction, the chief financial officer owned 217,675 shares of the company’s stock, valued at $2,564,211.50. This represents a 25.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.73% of the company’s stock.

Adherex Technologies Company Profile

(Get Free Report)

Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.

See Also

Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.